Developmental Pathways and Cancer: Wnt, Notch and Hedgehog joint with Stem Cells and Cancer Organizer(s): Frederic J. de Sauvage, Mariann Bienz and Jon C. Aster Date: February 02 - 07, 2014
Location: Fairmont Banff Springs, Banff, AB, CanadaAberrant activation of the Wnt, Notch and Hedgehog pathways via mutations or ligand overexpression has been implicated in a large number of cancer types where they are involved in functions ranging from tumor initiation to cancer stem cell maintenance and angiogenesis. These findings have triggered intensive efforts in both academia and industry to identify targets in these pathways and develop drugs for the treatment of certain tumors. Agents targeting each one of these three pathways have now reached clinical trials, and the first one of these, Vismodegib, a Hedgehog Pathway Inhibitor, was approved in 2012 for the treatment of advanced basal cell carcinoma. This meeting will allow scientists from both academia and industry to review the latest results on the role of these pathways in cancer and share their experience with the development of drugs in preclinical models and in the clinic. Issues ranging from predicting clinical efficacy in animal models to identification of predictive diagnostics and potential mechanisms of acquired resistance are key to the success of these agents and will require a combined effort from the entire community studying these pathways. Scholarship Deadline: October 11 2013 Discounted Abstract Deadline: October 11 2013 Abstract Deadline: November 6 2013 Discounted Registration Deadline: December 3 2013 We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Genentech, Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:  |